CASI Pharmaceuticals ( (CASIF) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CASI Pharmaceuticals, Inc. has filed a Form 12b-25 to notify investors of a delay in submitting its Form 20-F (Yearly Report) for the fiscal year ended December 31, 2025. The company, listed under SEC file number 001-41666, has not yet finalized the U.S. GAAP financial statements required for this annual filing.
Management states that the Form 20-F (Yearly Report) cannot be completed without unreasonable effort or expense at this time because the underlying audited financials are still being prepared. Once those U.S. GAAP financial statements are available, CASI expects to complete and submit the annual report.
The company has indicated it intends to file the delayed Form 20-F (Yearly Report) within the standard 15-calendar-day extension period permitted under the Form 12b-25 rules. All other required periodic reports over the past 12 months have been filed on time, suggesting this is an isolated timing issue rather than a broader filing breakdown.
Importantly for investors, CASI expects to disclose that there remains “substantial doubt” about its ability to continue as a going concern in the upcoming Form 20-F (Yearly Report). However, the company does not currently anticipate any significant change in results of operations compared to the prior fiscal year, according to its responses in the notification.
The company cautions that the notification contains forward-looking statements, including expectations about timing, audit completion, and going-concern disclosures. These statements may change once its independent registered public accounting firm completes the audit, and CASI emphasizes that it has no obligation to update such statements unless required by law.
CASI indicates it is working with its auditors to finalize the financial statements and complete the filing process as soon as practicable within the allowed extension. The notification is signed on behalf of the company by Chairman of the Board Wei-Wu He, dated April 21, 2026, underscoring board-level oversight of the late-filing process.
The most recent analyst rating on (CASIF) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASIF Stock Forecast page.
Spark’s Take on CASIF Stock
According to Spark, TipRanks’ AI Analyst, CASIF is a Neutral.
The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.
To see Spark’s full report on CASIF stock, click here.
More about CASI Pharmaceuticals
Average Trading Volume: 209,386
Technical Sentiment Signal: Sell
Current Market Cap: $2.32M
Learn more about CASIF stock on TipRanks’ Stock Analysis page.